Anti-human HER2 and human igf-ir bispecific antibody and its preparation method and use

Abstract

The invention provides a bispecific antibody capable of resisting human epidermal growth factor receptor 2 (HER2) and human insulin-like growth factor-IR (IGF-IR), and a preparation method and applications thereof. The bispecific antibody comprises a first antigen binding domain used for specific binding of HER2, and a second antigen binding domain used for specific binding of IGF-IR; the first antigen binding domain and the second antigen binding domain both comprise an antibody heavy chain variable structural domain (VH) and an antibody light chain variable structural domain (VL); the first antigen binding domain is an antibody variable structural domain capable of realizing specific binding with HER2; and the second antigen binding domain is an antibody variable structural domain capable of realizing specific binding with IGF-IR. The preparation method comprises following steps: synthesis of cDNA sequences used for coding the bispecific antibody; the cDNA sequences are inserted into a carrier for construction of an expression vector; expression of the expression vector is realized in host cells, and the bispecific antibody obtained by expression is separated and purified. The bispecific antibody can be used for preparing medicines used for treating human cancer, especially human breast cancer.

Description

technical field [0001] The invention relates to the technical field of biopharmaceuticals, in particular to a bispecific antibody against human epidermal growth factor receptor 2 (HER2) and human insulin-like growth factor-1 receptor (IGF-IR or IFG-1R) and its preparation Methods and uses. Background technique [0002] There are four receptors in the epidermal growth factor (EGF) tyrosine kinase receptor family, including erbB1 (EGFR or HER1), erbB2 (HER2 / neu), erbB3 (HER3) and erbB4 (HER4). This kind of receptor is a kind of transmembrane receptor, its extracellular fragment binds with ligands (except HER2) to form a homodimer or heterodimer to be activated, and its intracellular fragment has catechol amino acid kinase activity. There are four regions in the extracellular fragment, the I region and III region bind to the ligand, and the cysteine-rich region II and IV participate in the dimerization of the receptor (HynesNE&LaneHA.NatRevCancer.2005; 5(5): 341-54.). The e...

AI Technical Summary

Problems solved by technology

However, double-antibody combination therapy will be expensive, and it is also limited by the supply of two antibodies and a more complicated, lengthy and costly approval process, making it difficult to popularize clinically.

Images